

A population framework for predicting the proportion of people infected by the far-field airborne transmission of SARS-CoV-2 indoors

Christopher Iddon^a, Benjamin Jones^{a,*}, Patrick Sharpe^a, Muge Cevik^b,
Shaun Fitzgerald^c

^a*Department of Architecture and Built Environment, University of Nottingham,
Nottingham, UK*

^b*Infection and Global Health Division, School of Medicine, University of St Andrews, St
Andrews, UK*

^c*Department of Engineering, Cambridge University, Cambridge, UK*

Abstract

The number of occupants in a space influences the risk of far-field airborne transmission of the SARS-CoV-2 virus because the likelihood of having infectious and susceptible people both scale with the number of occupants. Mass-balance and dose-response models determine far-field transmission risks for an individual person and a population of people after sub-dividing a large *reference* space into 10 identical *comparator* spaces.

For a single infected person when the *per capita* ventilation rate is preserved, the dose received by an individual person in the *comparator* space is 10-times higher because the equivalent ventilation rate per infected person is lower.

However, accounting for population dispersion, such as the community infection rate, the probability of an infected person being present and un-

*Corresponding author

Email address: benjamin.jones@nottingham.ac.uk (Benjamin Jones)

certainty in their viral load, shows the probability of transmission increases with occupancy. Also, far-field transmission is likely to be a rare event that requires a set of Goldilocks conditions that are *just right*, when mitigation measures have limited effect.

Therefore, resilient buildings should deliver the equivalent ventilation rate required by standards and increase the space volume per person, but also require reductions in the viral loads and the infection rate of the wider population.

Keywords: relative exposure index, ventilation, aerosols, transmission risk, viral load, COVID-19

1 Nomenclature

2 \bar{I} mean number of infected people present

3 \bar{D} mean dose in a space where one infected person is present

4 \bar{I} mean number of infected people in a space that contains a potential
5 transmission event

6 $\overline{P(R)_I}$ mean individual probability of infection occurring in a scenario

7 $\overline{P(R)}$ mean individual infection risk that occurs in all potential transmission
8 scenarios

9 ϕ total removal rate (s^{-1})

10 C community infections rate (%)

11 D dose (viable virions)

12 G emission rate of RNA copies (RNA copies s^{-1})

13 I number of infected people

14 K fraction of aerosol particles absorbed by respiratory tract

15 k reciprocal of the probability that a single pathogen initiates an infec-
16 tion

17 L viral load (RNA copies per ml of respiratory fluid)

18 N number of occupants

19 N_s number of susceptible people exposed

20 $N_s(I)$ number of susceptible people exposed in spaces that contain I infected
21 people

22 N_t number of transmissions in the entire population

23 $N_t(I)$ number of transmissions that occur in spaces that contain I infected
24 people

25 N_{pop} population size

26 $P(0 < I < N)$ probability of a space containing a potential transmission

27 $P(I)$ probability of I infected people present

28 $P(L)$ probability of a viral load

29 $P(R)$ individual probability of infection

30 $P(S)$ probability of a person being both susceptible and exposed to the virus

31 q_{sus} susceptible person respiratory rate ($\text{m}^3 \text{s}^{-1}$)

32 T exposure period (s)

33 V space volume (m^3)

34 v viable fraction

35 **1. Introduction**

36 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a
37 novel virus that causes COVID-19. In 2020, it spread rapidly worldwide
38 causing a global pandemic. The main transmission mode of the virus occurs

39 when it is encapsulated within respiratory droplets and aerosols and inhaled
40 by a susceptible person [1]. These are most concentrated in the exhaled puff
41 of an infected person, which includes a continuum of aerosols and droplets of
42 all sizes as a multiphase turbulent gas cloud [2, 3]. The subsequent transport
43 of infectious aerosols from the exhaled puff occurs differently in outdoor and
44 indoor environments. Outside, air movement disrupts the exhaled puff, a
45 prodigious space volume rapidly dilutes it [4], and ultra-violet (UV) light
46 renders the virus biologically inviable over a short period of time [5]. Inside,
47 the magnitude of air movement is usually insufficient to disrupt the exhaled
48 puff, a finite space volume and lower ventilation rates concentrate aerosols in
49 the air, and there is usually less UV light [6]. Accordingly, transmission of
50 the virus occurs indoors more frequently than outdoors [7, 8], and inhaling
51 the exhaled puff at close contact is more likely to lead to an infective dose
52 than when inhaling indoor air at a distance where the virion laden aerosols
53 are diluted. This is consistent with the epidemiological understanding that
54 the SARS-CoV-2 virus is spread primarily by close contact where it might
55 be possible to smell a person's *coffee breath* [2, 3, 9, 10, 11]. However, it is
56 still possible for a susceptible person to inhale an infective dose of aerosol
57 borne virus, from shared indoor air, known as *far-field* airborne transmission,
58 and occurs at distances of > 2 m. Far-field transmission is linked to several
59 super spreading events and is often correlated with poor indoor ventilation,
60 long exposure times, and respiratory activities that increase aerosol and viral
61 emission, such as singing [12, 13, 14].

62 The number of occupants in a space can have an influence on the risk of
63 airborne transmission because the likelihood of having infectious and suscep-

64 tible people both scale with the number of occupants. Therefore, it may be
65 advantageous to sub-divide a large space into a number of identical smaller
66 spaces to reduce the transmission risk. Here, the space volume and ventila-
67 tion rate per person is kept constant, and occupants are divided into smaller
68 groups of people. The impact of this strategy on virus transmission is not
69 obvious. On one hand, the lower occupancy space reduces the probability of
70 an infected person being present, and also reduces the number of susceptible
71 people who are exposed to infected people. On the other hand, the ventilation
72 rate per infected person is likely to be smaller in the smaller space, increasing
73 the transmission risk for any susceptible people present. Accordingly, this
74 paper explores the relationship between occupancy and the probability of in-
75 fection, and how this affects an individual person and a population of people.
76 We take a theoretical approach to consider the infection risk for the popula-
77 tion of a large space and compare it to the same population distributed in a
78 number of smaller identical spaces.

79 We first consider the infection risk for a person using an existing analytical
80 model [15] to predict the dose and the probability that the dose leads to
81 infection. We then consider the infection risk for two equal populations
82 distributed evenly in either the big space or a number of smaller spaces,
83 by considering the community infection rate and the probability of infection
84 from a dose.

85 Section 2 outlines the modelling approach and the input data. Section 3
86 considers the personal risks from sub-division and Section 4 considers the
87 risks for a population. Section 5 discusses factors that affect infection risk
88 and limitation of the work.

89 2. Theoretical approach

90 An analytical model is used to predict the dose of viral genome copies of
91 an individual person and associated individual and population infection risks
92 of infection.

93 2.1. Dose and infection risk

94 The mass-balance model of Jones *et al.* [15] is used to predict the num-
95 ber of RNA copies absorbed by the respiratory tract of a person exposed to
96 aerosols in well mixed air over a significant period of time and combined with
97 the viable fraction, v , to give a dose, D .

$$D \simeq \frac{K q_{sus} G T v}{\phi V} \quad (1)$$

98 Here, K is the fraction of aerosol particles absorbed by respiratory tract,
99 q_{sus} is the respiratory rate ($\text{m}^3 \text{s}^{-1}$), G is the emission rate of RNA copies
100 (RNA copies s^{-1}) and is a function of the respiratory activity (see Jones *et*
101 *al.*), T is the exposure period (s), ϕ is the total removal rate (s^{-1}), which
102 represents the sum of all removal by ventilation, surface deposition, biological
103 decay, respiratory tract absorption, and filtration, and V is the space volume
104 (m^3). The product ϕV can be considered to be an *equivalent* ventilation
105 rate. The approach is common and has been used by others to investigate
106 exposure in well mixed air [16, 17].

107 For a full description of the model, a discussion of uncertainty in suitable
108 inputs, and a sensitivity analysis see Jones *et al.* [15]. The analysis shows that
109 the most sensitive parameter is G , the rate of emission of RNA copies. G is a
110 function of the *viral load* in the respiratory fluid, L (RNA copies per ml) and

111 the volume of aerosols emitted, which in turn is a function of exhaled breath
112 rate and respiratory activity; see Appendix Appendix A. The distribution
113 of the viral load within the infected population is reported to be log-normal
114 by Yang *et al.* [4], Weibull by Chen *et al.* [18], and Gamma by Ke *et al.* [19].
115 This suggests that the true distribution is unknown and so we assume that
116 it is log-normally distributed with a mode of 10^7 RNA copies per ml using the
117 data of Chen *et al.* [20]; see Table 2 and Figure 1. We explore variations in
118 these values in Section 2.3 and discuss their origin and uncertainty in them
119 in Section 5.5. The probability of a viral load, $P(L)$, can then be determined
120 using the standard equation for the log-normal probability distribution func-
121 tion.

122 The dose can be used to estimate a probability of infection using a dose-
123 response curve. However, there is no dose-response curve for SARS-CoV-2.
124 A number of studies [21, 16, 22] apply a dose curve for the SARS-CoV-1 virus,
125 which is a typical dose curve for corona viruses, and so it is applied here.
126 There are obvious problems with this extrapolation and they are discussed
127 in Section 5.5. The probability of infection of an individual person, $P(R)$, is
128 given by

$$P(R) = 1 - e^{-D/k} \quad (2)$$

129 where, k is the reciprocal of the probability that a single pathogen initiates
130 an infection. We use a value of $k = 410$ following DeDiego *et al.*[23].

131 *2.2. Individual risk*

132 A Relative Exposure Index (REI) is used to compare exposure risk for an
133 individual person between two spaces following Jones *et al.* [15]. Here, the
134 REI is the ratio of the dose, D , received by a susceptible occupant in each
135 of two spaces using Equation 1 where the *reference* space is the denominator
136 and the *comparator* space is the numerator. An advantage of using an REI
137 is that uncertainty in the viral load of respiratory fluid (RNA copies per ml),
138 which is used to determine the viral emission rate, G (RNA copies per m^3),
139 and the unknown dose response, cancels allowing scenarios to be compared.
140 When the REI is > 1 the comparator space is predicted to pose a greater risk
141 to an individual susceptible occupant because they inhale a larger dose in
142 the comparator scenario, although the absolute risk that this dose will lead
143 to a probability of infection is not considered. Any space that wishes to have
144 a REI of unity or less, must at least balance the parameters in Equation 1.

145 *2.3. Population infection risk*

146 A limitation of the REI is that it does not consider the probability of
147 encountering an infected person with the same viral load in each scenario.
148 The probability that a number of infected people, I , is present in a space,
149 $P(I)$, with a number of people present, N , is determined by considering the
150 community infections rate, C , and standard number theory for combinations.

$$P(I) = \frac{C^I(1 - C)^{(N-I)}N!}{I!(N - I)!} \quad (3)$$

151 The total number of transmissions that occur in a population, N_t , of N_{pop}
152 people, is the sum of the number of transmissions that occur in each trans-

153 mission scenario.

$$N_t = \sum_{I=1}^{N-1} N_t(I) \quad (4)$$

154 For a large population, the number of people infected in each space can be
155 given by the product of the number of susceptible people exposed, N_s , and
156 the mean individual probability of infection for a scenario, $\overline{P(R)}_I$.

$$N_t = \sum_{I=1}^{N-1} N_s(I) \overline{P(R)}_I \quad (5)$$

$$N_s(I) = P(I) \frac{N_{pop}}{N} (N - I) \quad (6)$$

157 where $N_s(I)$ denotes the number of susceptible people exposed in spaces
158 that contain I infected people, $P(I)$ is the probability that a space contains
159 I infected people, and $N_{pop} N^{-1}$ denotes the total number of spaces that
160 occur when a population N_{pop} is divided into groups of N people. Here, the
161 proportion of the population who are infected can be given by

$$PPI = \frac{N_t}{N_{pop}} = \sum_{I=1}^{N-1} P(I) \frac{N - I}{N} \overline{P(R)}_I \quad (7)$$

162 The exact solution for Equation 7 becomes increasingly difficult to eval-
163 uate as the space size increases. The calculation complexity is unlikely to be
164 justified given the uncertainties in both the modelling assumptions and the
165 available data. Therefore, simple approximations to the equation is desirable.

166 One approach is to express the number of transmission events using a
167 single mean individual risk for all possible transmission scenarios. Here, the

168 PPI can be expressed as

$$PPI = P(S)\overline{P(R)} \quad (8)$$

169 where $P(S)$ is the proportion of the population who are both exposed and
170 susceptible, and $\overline{P(R)}$ is the average individual infection risk that occurs in
171 all potential transmission scenarios.

172 Transmission events can only occur when there are both one or more
173 infected people present in a space ($I > 0$) and one or more susceptible people
174 are present ($I < N$). It follows that the probability of a space containing a
175 potential transmission event is given by

$$P(0 < I < N) = 1 - C^N - (1 - C)^N \quad (9)$$

176 As the number of occupants tends to infinity, the probability that the space
177 contains a potential transmission event approaches one, and is equal to zero
178 for single occupancy spaces. This suggests that it may be better to partition
179 a large space; see Section 1. Likewise, the probability that a space contains
180 susceptible people can be minimised by reducing the community infections
181 rate, as long as the community infections rate is less than half. Furthermore,
182 each space contains $(N - I)$ susceptible people in it. This allows the prob-
183 ability that a user of the space is both susceptible and exposed to be given
184 by

$$P(S) = (1 - C) - (1 - C)^N \quad (10)$$

185 where $P(S)$ approaches the proportion of susceptible people in the wider

186 community as $N \rightarrow \infty$.

187 Evaluating the mean individual risk is non-trivial. Here an approximation
188 is used, where

$$\overline{P(R)} = \int_1^{\infty} P(L) \left(1 - e^{-\frac{D}{k}\bar{I}}\right) dL \quad (11)$$

189 Here $P(L)$ is the probability of a person having a viral load L , and \bar{I} denotes
190 the mean number of infected people in a space that contains a potential
191 transmission event, and is given by

$$\bar{I} = \frac{N(C - C^N)}{P(0 < I < N)} \quad (12)$$

192 This allows the proportion of people infected in a scenario to be approximated
193 by

$$PPI \approx P(S) \int_1^{\infty} P(L) \left(1 - e^{-\frac{D}{k}\bar{I}}\right) dL \quad (13)$$

194 and is further simplified by assuming that mean infection probabilities are
195 adequately described using a mean viral load, which can often be found
196 directly from the literature. Here

$$PPI \approx P(S) \left(1 - e^{-\frac{\bar{D}}{k}\bar{I}}\right) \quad (14)$$

197 where \bar{D} is the mean dose received in the space where one infected person is
198 present.

199 *2.4. Scenarios*

200 The probabilities given in Section 2.3 can be used to consider how the
201 number of occupants may affect the relative exposure risk at population scale.
202 First, we define a reference space against which others are compared. This
203 space is an office, which is chosen because it is a common space that is well
204 regulated in most countries and has consistent occupancy densities. It has
205 an occupancy density of 10 m^2 per person, a floor to ceiling height of 3 m,
206 and an outdoor airflow rate of 10 l s^{-1} per person. There are 50 occupants
207 who are assumed to be continuously present for 8 hours breathing for 75%
208 and talking for 25%. Hereon it is known as the Big Office.

209 Then, we define a comparator space by subdividing the 50 person office
210 into 10 identical spaces. Each space preserves the occupancy density, the *per*
211 *capita* space volume, the outdoor airflow rate per person, and the air change
212 rate. Hereon each comparator space is known as the Small Office.

213 All scenario inputs are given in Table 1.

214 *2.5. Probabilistic estimates*

215 To investigate overdispersion in the model we use a Monte Carlo approach
216 that selects ten populations of 0.5×10^6 people and divides them into an equal
217 number of spaces, depending on the scenario; see Section 2.4. The predictions
218 confirm the mathematics described herein, and identify the uncertainty in the
219 number of transmissions that occur for each scenario; see Section 5.4. All
220 inputs are given in Tables 1 and 2.

221 We do not explore uncertainty in other inputs because this has been done
222 before [15] and to limit the exploration of uncertainty in the viral load and
223 the community infection rate.

Table 1: Scenario inputs and calculations of individual risk.

	Big Office Reference	Small Office Comparator
Number of occupants, N	50	5
Space Volume, V (m ³)	1500	150
<i>Per capita</i> volume, $V N^{-1}$ (m ³ per person)		30
Air flow rate, ψV (l s ⁻¹)	500	50
Air change rate, ψ (h ⁻¹)		1.2
Removal rate, ϕ (h ⁻¹)		2.26
Equivalent ventilation rate, ϕV (l s ⁻¹)	942	94.2
Exposure time, T (h)		8
Dose constant, k [23]		410
Viable fraction, v (%)		100
Viral load (RNA copies per ml) [20]		10 ⁷
Respiratory activity, <i>breathing: talking</i> (%)		72:25
Viral emission rate, G (RNA copies per hour)		394
Respiratory rate, q_{sus} (m ³ h ⁻¹)		0.56
Community infection rate, C		1:100
Dose, D (viable virions inhaled)	0.245	2.450
REI	1	10

All values converted to SI units before application.

224 3. Individual risk

225 The REI is the ratio of the dose predicted using Equation 1 for Big Office
 226 and Small Office; see Section 2.2. When the number of infected people and
 227 their respiratory activities, and the breathing rates of susceptible occupants,
 228 are identical in each space, the REI simplifies to a ratio of equivalent ven-
 229 tilation rates, ϕV . The equivalent ventilation rate is used to determine the
 230 steady state concentration of viable virions. Table 1 shows that the removal
 231 rate ϕ is identical in both spaces and so the REI becomes a simple ratio
 232 of the number of occupants. This suggests that, in the presence of a single
 233 infected person, the relative risk is 10 times higher in the Small Office. This

Table 2: Scenario inputs and calculations of population risk.

	Big Office Reference	Small Office Comparator
Viral load [20] (RNA copies per ml)	LN($2.1 \times 10^9, 2.0 \times 10^{10}$)	
$P(R)$ (%)	0.062	0.620
$P(I = 0)$ (%)	61	95
$P(0 < I < N)$ (%)	39	5
\bar{I}	1.27	1.02
$P(S)$ (%)	39	5
PPI (%)	1.59	0.43
TR		0.27

LN, log-normal(μ, σ)
All values converted to SI units before application.

234 occurs because the Small Office contains ten times fewer people than the Big
235 Office, and therefore the ventilation rate *per infector* is ten times smaller.

236 The equivalent ventilation rate per person, $\phi V N^{-1}$, is identical in both
237 spaces and, if it is desirable to preserve the equivalent ventilation per person
238 in two different spaces, the space volume per person must be preserved.

239 The removal rate, ϕ , includes the biological decay of the virus and the
240 deposition of aerosols onto surfaces. Both of these removal mechanisms are
241 space-volume dependent, and so their contribution to the removal of the
242 virus is greater in spaces with a larger volume. Therefore, increasing the
243 space volume per person also has the effect of reducing the REI. This has
244 obvious physical limitations and a simpler approach is to reduce the number
245 of people per unit of volume.

246 Equation 1 is used to calculate the dose of viable virions in each space
247 and Table 1 shows that the magnitudes of the doses are small. There is great

248 uncertainty in these values, attributable to modelling assumptions and in the
249 inputs given in Table 1, but an increase of an order of magnitude still leads
250 to a small dose. This fact is compounded by the value of unity for the viable
251 fraction, which has the effect that all RNA copies inhaled are viable, which
252 is unlikely. A viable fraction of unity was chosen because its true value is
253 currently unknown, and this assumption simplifies the analysis. The value
254 is clearly likely to be $\ll 100\%$ in reality, and so the actual doses would be
255 substantially lower than those estimated here. This suggests that far-field
256 transmission in buildings requires high viral emission rates, G , which are
257 likely to be a rare event.

258 The probability of an infection occurring when a susceptible occupant is
259 exposed to the dose reported in Table 1 is estimated using Equation 2 to
260 be $P(R) < 1\%$ for both spaces and is approximately 10 times greater in the
261 Small Office; see Table 2. Generally, this shows that the viral load has to
262 be greater in the Big Office than in the Small Office to achieve the same
263 $P(R)$ when $C < 1\%$. This is demonstrated by Figure 1, which describes the
264 relationship between the viral load in respiratory fluid (RNA copies per ml) in
265 each space attributable to any number of infected people and the consequent
266 $P(R)$ for a susceptible occupant, if the virus emission rate is assumed to be
267 linearly related to the viral load of the infected person.

268 For any viral load, L , the dose is calculated using Equation 1, and the
269 probability that it leads to an infection is calculated using Equation 2. This
270 creates a dose-response curve for both scenarios where factors that influence
271 the REI and, therefore, the dose, determine the viral loads necessary to
272 lead to a specific probability of infection. It also shows the relationship

273 between the viral load and the probability that a single infector has that
274 viral load, $P(L)$. The dashed vertical lines show the viral load required
275 to give a 50% probability that the dose will lead to an infection for each
276 scenario, $P(R) = 50\%$. The area under the blue curve to the right of each
277 vertical line is the probability that the viral load of the infected person leads
278 to $P(R) \geq 50\%$. The probability is much smaller for the Big Office, which
279 has the lower REI. This probability that an infected person has a viral load
280 that leads to $P(R) \geq 50\%$ is small, suggesting that the most likely outcome
281 is $P(R) \leq 50\%$. There is great uncertainty in the magnitude of these values,
282 particularly in $P(R)$ and in the conversion of a viral load to a virus emission
283 rate (see Section 2), but significant increases in them do not change the
284 general outcomes of the analysis. More generally, increasing the number of
285 occupants in a space while preserving the *per capita* volume has the effect
286 of moving the $P(R)$ curve to the right in Figure 1 and towards the tail of
287 the $P(L)$ curve, which reduces the likelihood of a sufficient viral load in the
288 space.

289 The $P(L)$ distribution curve could be flattened and shifted to the left of
290 Figure 1 by reducing the viral load of the infected population; for example,
291 vaccination is shown to clear the virus from the body quicker in infected
292 vaccinated people, which at a population scale could flatten the distribution
293 of $P(L)$ [24]. However, different variants of the SARS-CoV-2 virus could
294 increase the viral load, or the proportion of viable virions, or the infectivity
295 of virions, and move the curve to the right of Figure 1 [25, 26]. Other
296 respiratory viruses will have different distributions of the viral load but the
297 principles described here can be applied to them too.




Figure 1: An indication of the relationship between the viral load, L , and the consequent probability of infection, $P(R)$, in the Big Office (green) and Small Office (red) for a susceptible occupant, and the probability of a single infected person having a viral load, $P(L)$, (blue). Dashed vertical lines indicate the viral load required for $P(R) = 50\%$.

298 4. Population risks

299 The analysis in Section 3 is underpinned by the assumption that there is a
300 single infected person in each space. When the community infection rate (C)
301 is known, Equation 3 can be used to estimate the probability that a specific
302 number of infected people are present. When $C = 1\%$, in the Big Office
303 $P(I = 0)$ is 61%, $P(I = 1)$ is 31%, and $P(I > 1)$ is 9%. For the Small Office,
304 $P(I = 0)$ is 95%, $P(I = 1)$ is 5%, and $P(I > 1)$ is negligible. This shows
305 that the Big Office is over 12 times more likely to have an infected person
306 present than the Small Office, although Table 1 shows that the relative risk
307 is 10 times smaller in the Big Office than the Small Office when a single
308 infected person is present. However, it is much more likely that both spaces
309 do not have an infected person present, but when they are, the most likely
310 number of infected people is 1. The mean number of infected people is just
311 over 1 in both spaces when $C = 1\%$; see Equation 12.

312 Figure 1 shows the relationship between the probability of infection and
313 the probability of a person having a particular viral load. The viral load that
314 leads to an infection can be attributed to any number of infected people, but
315 the probability of having more than 1 infected person in a space is generally
316 small; see Equation 9. When only 1 infected person is assumed to be present,
317 Figure 1 also shows that the most probable viral loads do not lead to a
318 dose that leads to an infection in either the Small Office or the Big Office.
319 Therefore, the infected person must have a significant viral load to infect
320 susceptible occupants, which is an improbable event. The infection risk for
321 susceptible occupants is lower in the Big Office than the Small Office when
322 only 1 infected person is assumed to be present.

323 Bigger spaces that preserve the *per capita* volume given in Table 1, and
324 where $N \gg 50$, have a higher probability of susceptible people, $P(S)$, and
325 infected people, $P(0 < I < N)$. The effect on the aerosol concentration and
326 the dose depends on the space volume per infected person, $V I^{-1}$, relative
327 to that of the Reference Space, the Big Office. If $V I^{-1}$ decreases, then the
328 aerosol concentration, the dose, and the probability of infection, $P(R)$, all
329 increase. Accordingly, spaces with a high volume per occupant have a lower
330 infection risk. Here, spaces with high ceilings or low occupancy densities are
331 advantageous.

332 An increase in C also increases the probabilities of the presence of infected
333 people, $P(0 < I < N)$, and susceptible people, $P(S)$, in any space. This
334 increases the total viral load, the dose, D , and the probability of infection,
335 $P(R)$. Accordingly, maintaining a low community infection rate is important.
336 It is worth noting that C may vary by region where the occupants are from,
337 or by a particular population demographic [27]. Then, it is appropriate to use
338 C for that demographic, rather than using a national value. It is possible to
339 assess C by taking randomised samples from the population, such as the UK
340 Coronavirus (COVID-19) Infection Survey [28], which includes all infected
341 people at all stages of the disease. However, this survey includes symptomatic
342 people who are likely to be isolating and so the actual C is likely to be lower.

343 The information in Figure 1 can be combined to determine the total
344 proportion of people infected, PPI , in a space for all viral loads as a function
345 of the probability that an individual person has a particular viral load, $P(L)$,
346 the probability of the risk of infection, $P(R)$, the probability of the presence

347 of susceptible people $P(S)$, and the average number of infected people, \bar{I} .

$$PPI = \int_1^{\infty} P(L) P(R) P(S) \bar{I} dL \quad (15)$$

348 Figure 2 shows the proportion of people infected and the total viral load
349 (see Equation 15) where the area under each curve is the proportion of the
350 entire population infected for a community infection rate of $C = 1\%$, and
351 assuming that two equal populations, one distributed evenly across a number
352 of Small Office scenarios and the other distributed evenly across a number
353 of Big Office scenarios. Figure 2 indicates that the probability of far-field
354 infection is $PPI = 0.43\%$ in the Small Office and $PPI = 1.59\%$ in the Big
355 Office, which shows that the risk is 3 to 4 times higher in the Big Office.
356 The absolute values are likely to be much smaller than those calculated here
357 because of the conservative assumptions used to estimate the viral emission
358 from viral load (see Section 2.1), so the PPI may well be $\ll 1\%$ in both spaces
359 using less conservative assumptions; see the Supplementary Materials¹. This
360 indicates that although there are benefits of subdividing for a population,
361 their magnitude needs to be considered against other factors, such as the
362 overall work environment, labour and material costs, and inadvertent changes
363 to the ventilation system and strategy.

364 A transmission ratio, TR , gives an indication of relative risk of infection
365 where

$$TR = PPI_{comparator} / PPI_{reference} \quad (16)$$

¹[add SM link]

366 Here, the TR is 0.27.

367 The uncertainties in all of the values given here are significant and so
368 it is not possible to be confident in the magnitude of the PPI or the TR ,
369 but testing the model with a range of assumptions enables an assessment of
370 general trends; for example, how increasing occupancy and preserving *per*
371 *capita* space volume and ventilation rates impact the risk of infection and
372 how different mitigation measures, such as increasing the ventilation rate,
373 affect the relative PPI . These are discussed in Section 5.




Figure 2: An indication of the relationship between the proportion of a population infected for a particular viral load when the community infection rate is $C = 1\%$. The area under the curve represents the total proportion of people infected for the Small Office (red) and the Big Office (green).

374 5. Discussion

375 5.1. Ventilation and space volume




Figure 3: The effect of increasing the *per capita* ventilation rate, $\psi V N^{-1}$, in the Big Office on the *PPI* and the *TR* when the *per capita* ventilation rate in the Small Office is a constant 10l s^{-1} per person. All values are illustrative.

376 The quotient of the proportion of people infected in the two scenarios
377 gives a Transmission Ratio, TR , see Equation 16. Increasing the *per capita*
378 ventilation rate, $\psi V N^{-1}$, or space volume, $V N^{-1}$, in the Big Office reduces
379 the inverse of the TR . This has the effect of increasing the total removal rate,
380 ϕ , and reducing the dose and the probability of infection; see Equation 1 and
381 Figure 3. However, there is a law of diminishing returns in reducing the *PPI*
382 by increasing the ventilation rate because the dose is inversely proportional
383 to ϕ . Therefore, it is more important to increase the ventilation rate in a
384 poorly ventilated space than in a well ventilated space because the change in
385 the *PPI* is greater.

386 A similar effect is seen when increasing the *per capita* space volume in
387 the Big Office while maintaining a constant *per capita* ventilation in both
388 spaces. This is because the dose is inversely proportional to volume. Fur-
389 thermore, the product of the space volume and the total removal rate, ϕV ,
390 is proportional to the concentration of the virus in the air and, therefore, the
391 dose. The *per capita* ventilation rate is constant in both spaces and so the
392 air change rate in the Big Office decreases as its volume increases. However,
393 this reduction is offset by the surface deposition and biological decay rates,
394 which remain constant and have a greater effect on the value of the equivalent
395 ventilation rate, ψV , as the space volume increases; see Section 2.1.

396 Equation 1 assumes a steady-state concentration of the virus has been
397 reached based on the assumption that the exposure time, T , is significant.
398 However, the time taken to reach the steady-state concentration in large
399 spaces may be significant and affects the dose over shorter exposure periods.
400 This is an example of the *reservoir effect*, the ability of indoor air to act as
401 a fresh-air reservoir and absorb the impact of contaminant emissions. The
402 greater the space volume, the greater the effect. These factors highlight the
403 benefits of increasing the *per capita* space volume.

404 5.2. Occupancy

405 Figure 4 shows the effect of increasing the number of occupants in the
406 Big Office while maintaining both the *per capita* space volume, $V N^{-1}$, and
407 ventilation rate, $\psi V N^{-1}$. As the number of occupants increases, the *PPI*
408 increases at an ever diminishing rate because the magnitude of the equivalent
409 ventilation rate, ϕV , increases at a greater rate than the probability of the
410 mean number of infected people, \bar{I} .

411 However, if the volume and ventilation rate remain constant as the oc-
412 cupancy increases, Figure 5 shows that the PPI and the inverse of the TR
413 increase linearly with occupancy. Here, the total removal rate, ϕ , remains
414 constant but the *per capita* space volume and ventilation rate reduce. There-
415 fore, the Big Office could have 14 occupants and have the same PPI as the
416 Small Office occupied by 5 people. Extrapolating to two identical popula-
417 tions of 140 people split into 28 Small Offices with 5 people in each, and 10
418 Big Offices with 14 people in each, the same PPI can be achieved.

419 This suggests that reducing the number of occupants in a space is the
420 most effective means of reducing the inverse of TR towards unity. To achieve
421 the same goal by increasing the ventilation rate or the *per capita* space volume
422 would require unfeasibly large increases in both.




Figure 4: The effect of increasing the occupancy in the Big Office, where the space volume per person and ventilation rate per person is fixed at 30 m^3 and 10 l s^{-1} respectively, on the PPI (green) and TR (black). All values are illustrative.




Figure 5: The effect of increasing the occupancy in the Big Office where the space volume and ventilation flow rate is fixed for a designed occupancy of 50 people (1500 m^3 and 500 l s^{-1} , respectively), on the PPI and TR . All values are illustrative.

423 5.3. Community infection rate

424 Figure 6 shows that the community infection rate, C , has a significant
425 effect on the PPI and the TR . This is because it affects both the probability
426 of a viral load, $P(L)$, and the probability of having susceptible people in a
427 space, $P(S)$; see Equation 10. When $C > 1\%$, the probability of transmission
428 increases dramatically, suggesting that it strongly influences the spread of
429 the virus indoors. Figure 6 also shows that C only affects the TR when
430 the number of occupants, N , is less than the reciprocal of the community
431 infection rate, $N < 1/C$. Thereafter, the TR is constant irrespective of the
432 community infection rate; see the Supplementary Materials⁴.




Figure 6: The effect of increasing the community infection rate , C , on the PPI in the Big Office (green) and the Small Office (red) and on the TR (black). All values are illustrative.

433 5.4. Overdispersion

434 The Monte Carlo approach described in Section 2.5 was used to interro-
435 gate every scenario and estimate the number of susceptible people infected
436 when an infected person is present in the Big Office. The Monte Carlo pre-
437 dictions indicate that at least one infected person was present 39% of the
438 time, confirming the value of $P(S)$ given in Table 2 determined using Equa-
439 tion 9. But, it also indicates that there was no transmission in 90% of the
440 scenarios. When a transmission does occur, the most common outcome is a
441 single transmission event; see Figure 7. This indicates that the dose inhaled
442 by all susceptible people is usually small enough not to lead to an infection.
443 At least 40 susceptible occupants are infected in the Big Office only 0.5%
444 of the time, given the assumptions in Table 1. This suggests that so called
445 *super-spreader* events are rare; see Figure 7. This distribution reflects the

446 overdispersion of transmission recorded for SARS-CoV-2 and, although this
447 work only considers one transmission route, similar relationships between the
448 viral load and the number of transmission events may also be true for other
449 transmission routes [11, 29, 30, 31, 32].

450 Applying the MC approach to the Small Office shows that the overdis-
451 persion is less pronounced because there are fewer susceptible people, which
452 limits the number of people who can be infected when an infected person has
453 a high viral load. Here, 0.2% of all scenarios, and 25% of scenarios with at
454 least one transmission, had 4 infections of susceptible people. In the Small
455 Office, all 4 susceptible occupants were infected in 46% of scenarios where at
456 least one person was infected.

457 There are very few epidemiological examples of high secondary COVID-
458 19 transmission events where $> 80\%$ of occupants in a scenario are infected
459 and this suggests that our assumptions over-estimate the viral emission rate.
460 One reason is the assumption that all genome copies are viable virions, which
461 is very unlikely.

462 Figure 7 shows that the frequency of the number of susceptible people
463 infected is highest at zero and decreases as the number of susceptible peo-
464 ple infected increases. However, the frequency later increases as the number
465 of susceptible people infected approaches the number of occupants. This
466 reflects the shape of the probability of infection curve in Figure 1 where a
467 point is reached when the viral load leads to the infection of all susceptible
468 people, and a higher viral load cannot infect more people. The phenomena
469 is a function of occupancy and is less likely to occur as the number of occu-
470 pants increases because the viral load required to infect all susceptible people

471 increases, assuming that the *per capita* space volume and ventilation rate are
472 constant.




Figure 7: Uncertainty in the number of susceptible people infected in the Big Office Scenarios estimated using a Monte Carlo approach.

473 5.5. Limitations

474 Some limitations and uncertainties in this work have already been ad-
475 dressed, particularly those concerning the viral load and the dose-response
476 relationship. However, there are a number of other aspects that increase
477 uncertainty in it. Firstly, the models assume homogenous instantly mixed
478 indoor air to simplify the estimate of a dose. This assumption is unlikely to
479 be true in some spaces, especially in large spaces where the concentrations
480 of virions in the air is likely be a function of the distance from the infected
481 person. It is unclear at which space volume this assumption becomes less
482 useful, but it is likely to be a few thousand cubic metres.

483 The approach described in Section 2 only considers the far-field trans-
484 mission of virus, and not near-field transmission, which is likely to be the

485 dominant route of transmission. The concentration of the virus in aerosols
486 and droplets per unit volume of air is several orders of magnitude greater
487 closer to the infected person at distances of < 2 m [3, 9]. However, it is likely
488 that the method of calculating the probability of viral load of infected people,
489 $P(L)$, is also important for the dose received by near-field transmission and
490 should be explored further in the future.

491 The distribution of viral load of an infected person around the median will
492 affect the probability of transmission. We apply a log-normal distribution,
493 see Section 2, but another, such as the Weibull distribution, will affect the
494 transmission probabilities differently.

495 The model also assumes a naïve population of susceptible people, and it
496 is unclear whether a higher infective dose is required for susceptible people
497 who have a greater immune response obtained from vaccination or a previous
498 infection. This paper does not consider the effect of the magnitude of the
499 dose on subsequent disease severity. However, a recent review suggests that
500 it is highly unlikely there is a link between dose and disease severity [33].

501 There is uncertainty in the dose-response relationship and the propor-
502 tion of people infected. In the absence of knowledge, we have assumed that
503 the dose-response curve for SARS-CoV-1 also applies to SARS-CoV-2; see
504 Section 2.1. The SARS-CoV-1 dose-response curve was generated from four
505 groups of inoculated transgenic mice [23] that were genetically modified to
506 express the human protein receptor of the SARS-CoV-1 virus. In three of the
507 groups all mice were infected and in the fourth one-third were infected. The
508 dose-response curve was fitted to data from these four groups and, although
509 it is limited, it is sufficient to assume that the curve follows the exponential

510 distribution rather than the Beta-Poisson distribution. A further limitation is
511 that the response of humans to a dose of SARS-CoV-1 may vary significantly
512 from that of transgenic mice. For a further discussion, see the Supplemental
513 Material⁴. There is also uncertainty in the measurement of the viral load
514 used to challenge the study, and whether or not dose curves are valid for
515 predicting low probabilities of infection at very low virus titres. Other stud-
516 ies have used alternative dose-response curves for other coronaviruses, all of
517 which have similar uncertainties [21, 16].

518 The viral load of an infected person is the number of RNA copies per ml
519 of respiratory fluid, whereas the viral emission is the amount of RNA copies
520 per unit volume of exhaled breath; see Section 2.1. It has been established
521 that the viral load of an infected person increases in time from the moment of
522 infection and is highest just before, or at, the onset of COVID-19 symptoms.
523 As COVID-19 progresses the viral load reduces, normally within the first
524 week after the onset of symptoms [34, 35]. The viral load also varies between
525 people at any stage of the infection, which increases uncertainty in it [36, 37,
526 38, 19, 39, 18].

527 The viral load can be inferred from the *cycle threshold* values of real time
528 reverse transcription quantitative polymerase chain reaction (RT qPCR) na-
529 sopharyngeal (NP) swabs. This method assumes a direct correlation be-
530 tween the viral load of a swab and the viral load of respiratory fluid [40, 12].
531 RT qPCR is a semi-quantitative method because it requires a number of
532 amplification cycles to provide a positive signal of the SARS-CoV-2 genome,
533 which is proportional to the initial amount of viral genome in the original
534 sample. The cycle threshold is the number of polymerase chain reaction

535 cycles that are required before the chemical luminescence is read by the
536 equipment. The lower the starting amount of viral genome, the greater the
537 number of amplification cycles required. A calibrated standard curve is then
538 used to estimate the starting amount of viral genomic material. However,
539 the standard curve varies between test assays (investigative procedures) and
540 different RT qPCR thermal cyclers, the laboratory apparatus used to am-
541 plify segments of RNA. This method also assumes a complete doubling of
542 genetic material after each cycle. The exponential relationship means that
543 errors in the calculation of the initial quantity of genomic material are or-
544 ders of magnitude higher for low cycle counts than for high cycle counts.
545 Additionally, if genomic data is taken from NP swabs, the estimated concen-
546 tration of genomic material per unit volume is often related to the amount
547 of genomic material in the buffer solution² in which NP swabs are eluted and
548 used in the assay, and not necessarily to the amount in a patient's respira-
549 tory fluid. The amount of genomic material added to the buffer solution is
550 dependent on both a patient's viral load and the quality of the collection of
551 the NP sample, which is highly variable. Therefore, it is not possible to de-
552 termine absolute values of the viral load in a patient's respiratory fluid using
553 this method. However, data collected in this way is indicative of a range of
554 variability, much of which is likely to be proportional to the viral load of the
555 person at the time the sample was collected. Some recent data suggests that
556 the viral load of NP swabs may not reflect the amount of infectious material
557 present [19]. However, it is important to note that there are wide variations

²a *buffer solution* resists a change in its pH when a small quantity of acid or alkali is added to it

558 in the measured genomic material in NP swabs and that the viral load in
559 respiratory fluid is likely to vary by several orders of magnitude.

560 There is clearly uncertainty in the viral load of respiratory fluid. There is
561 also uncertainty in the viral concentration in respiratory aerosols and droplets
562 and the distribution is currently unclear. Some studies suggest that the
563 number of virions in small aerosols with a diameter of $< 1 \mu\text{m}$ is higher
564 than would be expected given the viral concentration in the respiratory fluid
565 [41, 42] and that for SARS-CoV-2 there may be more genomic material in
566 the smallest aerosols [43].

567 There is high variability between people in the total volume of aerosols
568 generated per unit volume of exhaled breath, and it is dependent upon the
569 respiratory activity, such as talking and singing, and the respiratory capacity
570 [44, 45, 46, 47]. Coleman *et al.* [43] show that SARS-CoV-2 genomic material
571 is detectable in expired aerosols from *some* COVID-19 patients, but not all
572 of them because 41% exhaled no detectable genomic material. Singing and
573 talking generally produce more genomic material than breathing, but there
574 is large variability between patients. This suggests that respiratory activities
575 that have previously been shown to increase aerosol mass also increase the
576 amount of viral genomic material emitted. However, the viral concentration
577 in aerosols cannot be determined because the study did not measure the
578 mass of aerosols generated. Coleman *et al.* also show that the variability in
579 the amount of genomic material measured in expired aerosols is consistent
580 with the variability of viral loads determined using swabs and saliva [43].

581 Similarly, Adenaiye *et al.* [48] detected genomic material in aerosols from
582 patients infected with SARS-CoV-2 who provided a sample of exhaled air

583 when talking or singing. Genomic material was more frequently detected
584 in exhaled aerosols when the viral load of saliva or mid-turbinate swabs
585 was high; $> 10^8$ and $> 10^6$ RNA copies for mid-turbinate swabs and saliva
586 samples, respectively. Furthermore, they were able to culture viable virus
587 from $< 2\%$ of fine aerosol samples. It should be noted that one positive
588 sample was from a culture developed from a fine aerosol sample that had
589 an amount of genomic material that was less than the detection limit of the
590 qRT PCR method and so could be an artefact. Nevertheless, this provides
591 some evidence to support the epidemiological evidence that viable virus can
592 exist in exhaled aerosols.

593 Miller *et al.* suggests that around 1 : 1000 genome copies are likely to
594 be infectious virion [49, 12]. Adenaiye *et al.* use mid-turbinate swabs to
595 estimate that there are around 1 : 10^4 viable virus per measured genome
596 copies[48]. We make the assumption that all genome copies are viable virion,
597 which either over-estimates their infectiousness when using the Coleman *et*
598 *al.* data, or is similar to the assumption of Miller *et al.* if the viable virion
599 emission rate is in the order of 1000 virions per hour; see Appendix Appendix
600 A.

601 **6. Conclusions**

602 The number of occupants in a space can influence the risk of far-field
603 airborne transmission that occurs at distances of > 2 m because the likelihood
604 of having infectious and susceptible people both scale with the number of
605 occupants. Therefore, mass-balance and dose-response models are applied
606 to determine if it is advantageous to sub-divide a large reference space into

607 a number of identical smaller comparator spaces to reduce the transmission
608 risk for an individual person and for a population of people.

609 The reference space is an office with a volume of 1500 m^3 occupied by
610 50 people over an 8 hour period, and has a ventilation rate of 10 l s^{-1} per per-
611 son. The comparator space is occupied by 5 people and preserves the oc-
612 cupancy period and the *per capita* volume and ventilation rate. The dose
613 received by an individual susceptible person in the comparator Small Office,
614 when a single infected person is present, is compared to that in the reference
615 Big Office for the same circumstances to give a relative exposure index (REI)
616 with a value of 10 in the Small Office. This REI is a measure of the risk of
617 a space relative to the geometry, occupant activities, and exposure times of
618 the reference scenario and so it is not a measure of the probability of infec-
619 tion. Accordingly, when a single infected person is assumed to be present, a
620 space with more occupants is less of a risk for susceptible people because the
621 equivalent ventilation rate per infected person is higher.

622 The assumption that only one infected person is present is clearly prob-
623 lematic because, for a community infection rate of 1%, the most likely number
624 of infected people in a 50 person space is none. A transmission event can
625 only occur when there are both one or more infected people present in a
626 space and one or more susceptible people are present. The probability of a
627 transmission event occurring increases with the number of occupants and the
628 community infection rate; for example, the Big Office is over 12 times more
629 likely to have infected people present than the Small Office. However, the
630 geometry and ventilation rate in a larger space are non-linearly related to
631 the number of infected and susceptible people and so their relationship with

632 the probability of a transmission event occurring is also non-linear. These
633 effects are evaluated by considering a large population of people. But, this
634 introduces uncertainty in factors that vary across the population, such as the
635 viral load of an infected person, defined as the number of RNA copies per ml
636 of respiratory fluid. The viral load varies over time and between people at
637 any stage of the infection.

638 By applying a distribution of viral loads across a population of infected
639 people, secondary transmissions (new infections) are found to be likely to
640 occur only when the viral load is high, although the probabilities of this
641 occurring in the Big Office and the Small Office are low. This makes it
642 hard to distinguish the route of transmission epidemiologically. Generally,
643 the viral load must be greater in the Big Office than in the Small Office to
644 achieve the same proportion of the population infected when the community
645 infection rate is $\leq 1\%$. The viable fraction is unknown but a value of unity
646 was chosen for computational ease, yet the estimated doses and infection
647 probabilities are small. Therefore, it is likely that far-field transmission is a
648 rare event that requires a set of Goldilocks conditions that are *just right*.

649 There are circumstances where the magnitude of the total viral load of
650 the infected people is too high to affect the probability of secondary trans-
651 missions by increasing ventilation and space volume. Conversely, when the
652 total viral load is very small the dose is too low to lead to an infection in
653 any space irrespective of its geometry or the number of susceptible people
654 present. There is a law of depreciating returns for the dose and, therefore, the
655 probability of infection, and the ventilation rate because they are inversely
656 related. Accordingly, it is better to focus on increasing effective ventilation

657 rates in under-ventilated spaces rather than increasing ventilation rates above
658 those prescribed by standards, or increasing effective ventilation rates using
659 air cleaners, in already well-ventilated spaces.

660 There are significant uncertainties in the modelling assumptions and the
661 data used in the analysis and it is not possible to have confidence in the calcu-
662 lated magnitudes of doses or the proportions of people infected. However, the
663 general trends and relationships described herein are less uncertain and may
664 also apply to airborne pathogens other than SARS-CoV-2 at the population
665 scale. Accordingly, it is possible to say that there are benefits of subdividing
666 a population, but their magnitudes need to be considered against other fac-
667 tors, such as the overall working environment, labour and material costs, and
668 inadvertent changes to the ventilation system and strategy. However, it is
669 likely that the benefits do not outweigh the costs in existing buildings when
670 a less conservative viable fraction is used because it decreases the magnitude
671 of the benefits significantly. It is likely to be more cost-effective to consider
672 the advantages of partition when designing new resilient buildings because
673 the consequences can be considered from the beginning.

674 There are other factors that will reduce the risk of transmission in ex-
675 isting buildings. Local and national stakeholders can seek to maintain low
676 community infection rates, detect infected people with high viral loads us-
677 ing rapid antigen tests and isolate them (see the Supplementary Materials³),
678 reduce the variance and magnitude of the viral load in a population by en-
679 couraging vaccination. Changes can be made to the use of existing buildings
680 and their services, such as reducing the occupancy density of a space below

³[add SM link]

681 the level it was designed for while preserving the magnitude of the ventila-
682 tion rate, reducing exposure times, and ensuring compliance with ventilation
683 standards.

684 **Acknowledgements**

685 The authors acknowledge the Engineering and Physical Sciences Research
686 Council (EP/W002779/1) who financially supported this work. They are also
687 grateful to Constanza Molina for her comments on this paper.

688 **Appendix A. Estimating viral emission from viral load**

689 We assume that the RNA copies per ml concentration is constant in aerosols
690 and in NP swabs and then we use the assumptions of Jones *et al.* [15] to con-
691 vert a NP viral load into a virus emission rate. This method follows Jones *et*
692 *al.* and is derived from the work of Morawskwa *et al.* who determine vol-
693 ume distribution aerosols for different respiratory activities, and is similar
694 to that used by Lelieveld *et al.* [15, 17, 47]. Table A.3 shows the estimated
695 virus emission rate for different respiratory activities when the viral load
696 is 10^7 RNA copies per ml. For comparison, median measured values of virus
697 emission in aerosols from Coleman *et al.* are given. These values were mea-
698 sured by collecting RNA copies from COVID-19 patients, where the median
699 cycle threshold, required to process diagnostic samples, was 16. [43].

700

Table A.3: Estimated emission rates from an infected person with a viral load of 10^7 RNA copies per ml compared to measured emission rates from patients with a median cycle threshold of 16 [43]

	Estimated RNA copies h^{-1}	Measured median RNA copies h^{-1}
Breathing	203	127
Voiced counting (talking)	967	1912
Vocalisation (singing)	6198	2856
Breathing:talking 25:75	394	573*

*calculated using measured values for breathing and talking.

701 Additionally, unpublished work by Adenaiye *et al.* measured viral genome
702 in patients infected by the SARS-CoV-2 alpha variant, who were breathing
703 and talking, in coarse ($> 5 \mu\text{m}$) and fine ($\leq 5 \mu\text{m}$) aerosols with a total geo-
704 metric mean of 1440 RNA copies h^{-1} and a maximum of 3×10^5 RNA copies h^{-1}
705 [48]. These are greater than the estimated values given in Table A.3, but the
706 viral load, measured by genome copies from mid-turbinate swabs, was gen-
707 erally orders of magnitude higher than 10^7 RNA copies per ml.

708 In Section 4, the inhaled dose is calculated for all possible viral loads.
709 Here, it should be noted that the calculated RNA copies emission rate is as-
710 sumed to be linearly related to the viral load of respiratory fluids, so that
711 a viral load of 10^8 RNA copies per ml has a ten-fold greater emission rate.
712 For comparison, a virus emission rate of 394 RNA copies h^{-1} (assumed for a
713 viral load of 10^7 RNA copies per ml) leads to an individual doses of around
714 2.2 RNA copies and 0.2 RNA copies for the Small Office and Big Office sce-
715 narios, respectively.

716 The calculated emission rate of viral genome for a viral load of 10^7 RNA copies per ml
717 is a reasonable fit to the Coleman *et al.* and Adenaiye *et al.* data. For further
718 details see the Supplementary Materials⁴.

⁴[add SM link]

719 **References**

- 720 [1] C. C. Wang, K. A. Prather, J. Sznitman, J. L. Jimenez, S. S. Lakdawala,
721 Z. Tufekci, L. C. Marr, Airborne transmission of respiratory viruses, *Sci-*
722 *ence* 373 (6558) (2021) eabd9149. doi:10.1126/science.abd9149.
723 URL [https://www.sciencemag.org/lookup/doi/10.1126/science.](https://www.sciencemag.org/lookup/doi/10.1126/science.abd9149)
724 [abd9149](https://www.sciencemag.org/lookup/doi/10.1126/science.abd9149)
- 725 [2] L. Bourouiba, Turbulent Gas Clouds and Respiratory Pathogen Emis-
726 sions: Potential Implications for Reducing Transmission of COVID-19,
727 *JAMA - Journal of the American Medical Association* 323 (18) (2020)
728 1837–1838. doi:10.1001/jama.2020.4756.
- 729 [3] G. Cortellessa, L. Stabile, F. Arpino, D. Faleiros, W. van den Bos,
730 L. Morawska, G. Buonanno, Close proximity risk assessment for SARS-
731 CoV-2 infection, *Science of The Total Environment* 794 (2021) 148749.
732 doi:10.1016/j.scitotenv.2021.148749.
733 URL <https://doi.org/10.1016/j.scitotenv.2021.148749>
- 734 [4] Q. Yang, T. K. Saldi, P. K. Gonzales, E. Lasda, C. J. Decker, K. L.
735 Tat, M. R. Fink, C. R. Hager, J. C. Davis, C. D. Ozeroff, D. Muhrad,
736 S. K. Clark, W. T. Fattor, N. R. Meyerson, C. L. Paige, A. R. Gilchrist,
737 A. Barbachano-Guerrero, E. R. Worden-Sapper, S. S. Wu, G. R. Bris-
738 son, M. B. McQueen, R. D. Dowell, L. Leinwand, R. Parker, S. L.
739 Sawyer, Just 2 percent of sars-cov-2 positive individuals carry 90 per-
740 cent of the virus circulating in communities, *Proceedings of the National*
741 *Academy of Sciences* 118 (21) (2021) e2104547118. doi:10.1073/pnas.

742 2104547118.

743 URL <http://www.pnas.org/lookup/doi/10.1073/pnas.2104547118>

744 [5] P. Dabisch, M. Schuit, A. Herzog, K. Beck, S. Wood, M. Krause,
745 D. Miller, W. Weaver, D. Freeburger, I. Hooper, B. Green, G. Williams,
746 B. Holland, J. Bohannon, V. Wahl, J. Yolitz, M. Hevey, S. Ratnesar-
747 Shumate, The influence of temperature, humidity, and simulated sun-
748 light on the infectivity of SARS-CoV-2 in aerosols, *Aerosol Science*
749 *and Technology* 55 (2) (2021) 142–153. doi:10.1080/02786826.2020.
750 1829536.

751 URL [https://www.tandfonline.com/doi/full/10.1080/02786826.](https://www.tandfonline.com/doi/full/10.1080/02786826.2020.1829536)
752 2020.1829536

753 [6] Z. Liu, Q. Guo, L. Zou, H. Zhang, M. Zhang, F. Ouyang, J. Su, W. Su,
754 J. Xu, H. Lin, J. Sun, J. Peng, H. Jiang, P. Zhou, H. Zhen, T. Liu,
755 R. Che, H. Zeng, Z. Zheng, J. Yu, L. Yi, J. Wu, J. Chen, H. Zhong,
756 X. Deng, M. Kang, O. G. Pybus, M. Hall, K. A. Lythgoe, Viral infection
757 and transmission in a large well- traced outbreak caused by the Delta
758 SARS-CoV-2 variant, *Virological.org* (2021).

759 URL <https://virological.org/t/viral-infection-and-transmission-in-a-large-wel>
760 724

761 [7] T. C. Bulfone, M. Malekinejad, G. W. Rutherford, N. Razani, Out-
762 door Transmission of SARS-CoV-2 and Other Respiratory Viruses: A
763 Systematic Review, *The Journal of infectious diseases* 223 (4) (2021)
764 550–561. doi:10.1093/infdis/jiaa742.

765 [8] M. Weed, A. Foad, Rapid scoping review of evidence of outdoor trans-

- 766 mission of COVID-19, medRxiv (2020) 1–16doi:10.1101/2020.09.04.
767 20188417.
- 768 [9] N. Zhang, W. Chen, P. T. Chan, H. L. Yen, J. W. T. Tang, Y. Li, Close
769 contact behavior in indoor environment and transmission of respiratory
770 infection, *Indoor Air* 30 (4) (2020) 645–661. doi:10.1111/ina.12673.
- 771 [10] SAGE, SARS-COV-2 Transmission routes and environments, Tech.
772 Rep. October, SAGE, UK (2020).
773 URL [https://assets.publishing.service.gov.uk/government/
774 uploads/system/uploads/attachment_data/file/933225/S0824_
775 SARS-CoV-2_Transmission_routes_and_environments.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/933225/S0824_SARS-CoV-2_Transmission_routes_and_environments.pdf)
- 776 [11] K. Escandón, A. L. Rasmussen, I. I. Bogoch, E. J. Murray, K. Es-
777 candón, S. V. Popescu, J. Kindrachuk, COVID-19 false dichotomies
778 and a comprehensive review of the evidence regarding public health,
779 COVID-19 symptomatology, SARS-CoV-2 transmission, mask wear-
780 ing, and reinfection, *BMC Infectious Diseases* 21 (1) (2021) 710.
781 arXiv:arXiv:1011.1669v3, doi:10.1186/s12879-021-06357-4.
782 URL [https://osf.io/k2d84/https://bmcinfectdis.
783 biomedcentral.com/articles/10.1186/s12879-021-06357-4](https://osf.io/k2d84/https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06357-4)
- 784 [12] S. L. Miller, W. W. Nazaroff, J. L. Jimenez, A. Boerstra, S. J. Dancer,
785 J. Kurnitski, L. C. Marr, L. Morawska, C. Noakes, Transmission of
786 SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley
787 Chorale superspreading event, *Indoor Air* in press (2020). doi:doi.
788 org/10.1111/ina.12751.

- 789 [13] D. Hijnen, A. Marzano, K. Eyerich, C. GeurtsvanKessel, A. Giménez-
790 Arnau, P. Joly, C. Vestergaard, M. Sticherling, E. Schmidt, Sars-cov-2
791 transmission from presymptomatic meeting attendee, germany., Emerg-
792 ing infectious diseases 26 (8) (2020). doi:10.3201/eid2608.201235.
- 793 [14] L. M. Groves, L. Usagawa, J. Elm, E. Low, A. Manuzak, J. Quint, K. E.
794 Center, A. M. Buff, S. K. Kemble, Community Transmission of SARS-
795 CoV-2 at Three Fitness Facilities — Hawaii, June–July 2020, MMWR
796 Surveillance Summaries 70 (9) (2021) 316–320. doi:10.15585/mmwr.
797 mm7009e1.
- 798 [15] B. Jones, P. Sharpe, C. Iddon, E. A. Hathway, C. J. Noakes, S. Fitzger-
799 ald, Modelling uncertainty in the relative risk of exposure to the SARS-
800 CoV-2 virus by airborne aerosol transmission in well mixed indoor air,
801 Building and Environment 191 (October 2020) (2021) 107617. doi:
802 10.1016/j.buildenv.2021.107617.
803 URL <https://doi.org/10.1016/j.buildenv.2021.107617>
- 804 [16] H. Parhizkar, K. G. Van Den Wymelenberg, C. N. Haas, R. L. Corsi, A
805 Quantitative Risk Estimation Platform for Indoor Aerosol Transmission
806 of COVID-19, Risk Analysis 0 (0) (2021). doi:10.1111/risa.13844.
- 807 [17] J. Lelieveld, F. Helleis, S. Borrmann, Y. Cheng, F. Drewnick, G. Haug,
808 T. Klimach, J. Sciare, H. Su, U. Pöschl, Model calculations of aerosol
809 transmission and infection risk of covid-19 in indoor environments, Inter-
810 national Journal of Environmental Research and Public Health 17 (21)
811 (2020) 1–18. doi:10.3390/ijerph17218114.

- 812 [18] P. Z. Chen, N. Bobrovitz, Z. Premji, M. Koopmans, D. N. Fisman, F. X.
813 Gu, Heterogeneity in transmissibility and shedding SARS-CoV-2 via
814 droplets and aerosols, *eLife* 10 (2021) 1–32. doi:10.7554/eLife.65774.
- 815 [19] R. Ke, P. P. Martinez, R. L. Smith, L. L. Gibson, A. Mirza, M. Conte,
816 N. Gallagher, C. H. Luo, J. Jarrett, A. Conte, M. Farjo, K. K. O.
817 Walden, G. Rendon, C. J. Fields, R. Fredrickson, D. C. Edmonson,
818 M. E. Baughman, K. K. Chiu, J. Yedetore, J. Quicksall, A. N. Owens,
819 J. Broach, Daily sampling of early SARS-CoV-2 infection reveals
820 substantial heterogeneity in infectiousness, *medRxiv* (July 12th 2021)
821 (2021) 1–23. doi:<https://doi.org/10.1101/2021.07.12.21260208>.
822 URL [https://www.medrxiv.org/content/10.1101/2021.07.12.](https://www.medrxiv.org/content/10.1101/2021.07.12.21260208v1)
823 [21260208v1](https://www.medrxiv.org/content/10.1101/2021.07.12.21260208v1)
- 824 [20] P. Z. Chen, N. Bobrovitz, Z. Premji, M. Koopmans, D. N. Fisman, F. X.
825 Gu, Sars-cov-2 shedding dynamics across the respiratory tract, sex, and
826 disease severity for adult and pediatric covid-19, *eLife* 10 (2021) e70458.
827 doi:10.7554/eLife.70458.
828 URL <https://doi.org/10.7554/eLife.70458>
- 829 [21] T. Watanabe, T. A. Bartrand, M. H. Weir, T. Omura, C. N. Haas,
830 Development of a dose-response model for sars coronavirus. risk analysis:
831 an official publication of the society for risk analysis, *Risk Anal* 30 (7)
832 (2010) 1129–1138. doi:10.1111/j.1539-6924.2010.01427.x.
- 833 [22] X. Zhang, J. Wang, Dose-response Relation Deduced for Coronaviruses
834 From Coronavirus Disease 2019, Severe Acute Respiratory Syndrome,
835 and Middle East Respiratory Syndrome: Meta-analysis Results and

- 836 its Application for Infection Risk Assessment of Aerosol Transmission,
837 Clinical Infectious Diseases (Xx Xxxx) (2020) 1–5. doi:10.1093/cid/
838 ciaa1675.
- 839 [23] M. L. DeDiego, L. Pewe, E. Alvarez, M. T. Rejas, S. Perlman, L. En-
840 juanes, Pathogenicity of severe acute respiratory coronavirus deletion
841 mutants in hACE2 transgenic mice, *Virology* 376 (2) (2008) 379–389.
842 doi:<https://doi.org/10.1016/j.virol.2008.03.005>.
843 URL [https://www.sciencedirect.com/science/article/pii/
844 S004268220800175X](https://www.sciencedirect.com/science/article/pii/S004268220800175X)
- 845 [24] P. Y. Chia, S. W. X. Ong, C. J. Chiew, L. W. Ang, J.-M. Chavatte,
846 T.-M. Mak, L. Cui, S. Kalimuddin, W. N. Chia, C. W. Tan, L. Y. A.
847 Chai, S. Y. Tan, S. Zheng, R. T. P. Lin, L. Wang, Y.-S. Leo, V. J. Lee,
848 D. C. Lye, B. E. Young, Virological and serological kinetics of SARS-CoV-
849 2 delta variant vaccine-breakthrough infections: a multi-center cohort
850 study, medRxiv (2021) 2021.07.28.21261295.
- 851 [25] A. Singanayagam, S. Hakki, J. Dunning, K. J. Madon, M. A. Crone,
852 A. Koycheva, N. Derqui-Fernandez, J. L. Barnett, M. G. Whitfield,
853 R. Varro, A. Charlett, R. Kundu, J. Fenn, J. Cutajar, V. Quinn,
854 E. Conibear, W. Barclay, P. S. Freemont, G. P. Taylor, S. Ahmad,
855 M. Zambon, N. M. Ferguson, A. Lalvani, A. Badhan, S. Dustan,
856 C. Tejpal, A. V. Ketkar, J. S. Narean, S. Hammett, E. McDermott,
857 T. Pillay, H. Houston, C. Luca, J. Samuel, S. Bremang, S. Evetts,
858 J. Poh, C. Anderson, D. Jackson, S. Miah, J. Ellis, A. Lackenby,
859 Community transmission and viral load kinetics of the SARS-CoV-2

- 860 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in
861 the UK: a prospective, longitudinal, cohort study, *The Lancet Infectious*
862 *Diseases* 3099 (21) (oct 2021). doi:10.1016/S1473-3099(21)00648-4.
863 URL [https://linkinghub.elsevier.com/retrieve/pii/
864 S1473309921006484](https://linkinghub.elsevier.com/retrieve/pii/S1473309921006484)
- 865 [26] D. W. Eyre, D. Taylor, M. Purver, D. Chapman, T. Fowler, K. Pouwels,
866 A. S. Walker, T. E. A. Peto, The impact of SARS-CoV-2 vacci-
867 nation on Alpha and Delta variant transmission, *medRxiv* (2021)
868 2021.09.28.21264260.
869 URL [http://medrxiv.org/content/early/2021/09/29/2021.09.
870 28.21264260.abstract](http://medrxiv.org/content/early/2021/09/29/2021.09.28.21264260.abstract)
- 871 [27] M. Cevik, S. D. Baral, Networks of SARS-CoV-2 transmission., *Science*
872 (New York, N.Y.) 373 (6551) (2021) 162–163. doi:10.1126/science.
873 abg0842.
874 URL <http://www.ncbi.nlm.nih.gov/pubmed/34244400>
- 875 [28] ONS, ONS Coronavirus (COVID-19) Infection Survey.
876 URL [https://www.ons.gov.uk/peoplepopulationandcommunity/
877 healthandsocialcare/conditionsanddiseases/bulletins/
878 coronaviruscovid19infectionsurveypilot/previousReleases](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/previousReleases)
- 879 [29] Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei,
880 S. A. Truelove, T. Zhang, W. Gao, C. Cheng, X. Tang, X. Wu,
881 Y. Wu, B. Sun, S. Huang, Y. Sun, J. Zhang, T. Ma, J. Lessler,
882 T. Feng, Epidemiology and transmission of COVID-19 in 391 cases
883 and 1286 of their close contacts in Shenzhen, China: a retrospective

- 884 cohort study, *The Lancet Infectious Diseases* 20 (8) (2020) 911–919.
885 doi:10.1016/S1473-3099(20)30287-5.
- 886 [30] J. E. Lemieux, K. J. Siddle, B. M. Shaw, C. Loreth, S. F. Schaffner,
887 A. Gladden-Young, G. Adams, T. Fink, C. H. Tomkins-Tinch, L. A.
888 Krasilnikova, K. C. DeRuff, M. Rudy, M. R. Bauer, K. A. Lagerborg,
889 E. Normandin, S. B. Chapman, S. K. Reilly, M. N. Anahtar, A. E.
890 Lin, A. Carter, C. Myhrvold, M. E. Kembball, S. Chaluvadi, C. Cusick,
891 K. Flowers, A. Neumann, F. Cerrato, M. Farhat, D. Slater, J. B. Harris,
892 J. A. Branda, D. Hooper, J. M. Gaeta, T. P. Baggett, J. O’Connell,
893 A. Gnirke, T. D. Lieberman, A. Philippakis, M. Burns, C. M. Brown,
894 J. Luban, E. T. Ryan, S. E. Turbett, R. C. LaRocque, W. P. Hanage,
895 G. R. Gallagher, L. C. Madoff, S. Smole, V. M. Pierce, E. Rosenberg,
896 P. C. Sabeti, D. J. Park, B. L. MacInnis, Phylogenetic analysis of SARS-
897 CoV-2 in Boston highlights the impact of superspreading events, *Science*
898 371 (6529) (2021). doi:10.1126/science.abe3261.
- 899 [31] D. Miller, M. A. Martin, N. Harel, O. Tirosh, T. Kustin, M. Meir,
900 N. Sorek, S. Gefen-Halevi, S. Amit, O. Vorontsov, A. Shaag, D. Wolf,
901 A. Peretz, Y. Shemer-Avni, D. Roif-Kaminsky, N. M. Kopelman,
902 A. Huppert, K. Koelle, A. Stern, Full genome viral sequences inform
903 patterns of SARS-CoV-2 spread into and within Israel, *Nature Commu-*
904 *nications* 11 (1) (2020). doi:10.1038/s41467-020-19248-0.
905 URL <http://dx.doi.org/10.1038/s41467-020-19248-0>
- 906 [32] J. Riou, C. L. Althaus, Pattern of early human-to-human trans-
907 mission of Wuhan 2019 novel coronavirus (2019-nCoV), Decem-

- 908 ber 2019 to January 2020, *Eurosurveillance* 25 (4) (2020) 1–5.
909 doi:10.2807/1560-7917.ES.2020.25.4.2000058.
910 URL [http://dx.doi.org/10.2807/1560-7917.ES.2020.25.4.](http://dx.doi.org/10.2807/1560-7917.ES.2020.25.4.2000058)
911 2000058
- 912 [33] L. M. Brosseau, K. Escandón, A. K. Ulrich, A. L. Rasmussen, C. J. Roy,
913 G. J. Bix, S. V. Popescu, K. Moore, M. T. Osterholm, SARS-CoV-2
914 Dose, Infection, and Disease Outcomes for COVID-19 – A Review, *Clinical Infectious Diseases* 54 (2021) 1–54. doi:10.1093/cid/ciab903.
915 URL [https://academic.oup.com/cid/advance-article/doi/10.](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab903/6397523)
916 1093/cid/ciab903/6397523
- 918 [34] M. Cevik, K. Kuppalli, J. Kindrachuk, M. Peiris, *Virology*, transmission,
919 and pathogenesis of SARS-CoV-2, *The BMJ* 371 (2020) 1–6. doi:10.
920 1136/bmj.m3862.
- 921 [35] M. Cevik, M. Tate, O. Lloyd, A. E. Maraolo, J. Schafers, A. Ho,
922 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, du-
923 ration of viral shedding, and infectiousness: a systematic review and
924 meta-analysis, *The Lancet Microbe* 2 (1) (2021) e13–e22. doi:10.1016/
925 S2666-5247(20)30172-5.
926 URL [http://dx.doi.org/10.1016/S2666-5247\(20\)30172-5](http://dx.doi.org/10.1016/S2666-5247(20)30172-5)
- 927 [36] Y. Pan, D. Zhang, P. Yang, L. L. Poon, Q. Wang, Viral load of SARS-
928 CoV-2 in clinical samples, *The Lancet Infectious Diseases* 20 (4) (2020)
929 411–412. doi:10.1016/S1473-3099(20)30113-4.
930 URL [http://dx.doi.org/10.1016/S1473-3099\(20\)30113-4](http://dx.doi.org/10.1016/S1473-3099(20)30113-4)

- 931 [37] S. Karimzadeh, R. Bhopal, H. Nguyen Tien, Review of infective
932 dose, routes of transmission and outcome of COVID-19 caused
933 by the SARS-COV-2: comparison with other respiratory viruses–
934 CORRIGENDUM, *Epidemiology and Infection* 149 (2021) e116.
935 doi:10.1017/S0950268821001084.
936 URL [https://www.cambridge.org/core/product/identifier/
937 S0950268821001084/type/journal_article](https://www.cambridge.org/core/product/identifier/S0950268821001084/type/journal_article)
- 938 [38] R. Challen, E. Brooks-Pollock, J. M. Read, L. Dyson, K. Tsaneva-
939 Atanasova, L. Danon, Risk of mortality in patients infected with SARS-
940 CoV-2 variant of concern 202012/1: Matched cohort study, *The BMJ*
941 372 (2021) 1–10. doi:10.1136/bmj.n579.
- 942 [39] A. S. Walker, E. Pritchard, T. House, J. V. Robotham, P. J. Birrell,
943 I. Bell, J. Bell, J. Newton, J. Farrar, I. Diamond, R. Studley, J. Hay,
944 K.-D. Vihta, T. E. Peto, N. Stoesser, P. C. Matthews, D. W. Eyre,
945 K. Pouwels, Ct threshold values, a proxy for viral load in community
946 SARS-CoV-2 cases, demonstrate wide variation across populations and
947 over time, *eLife* 10 (jul 2021). doi:10.7554/eLife.64683.
948 URL <https://elifesciences.org/articles/64683>
- 949 [40] G. Buonanno, L. Stabile, L. Morawska, Estimation of airborne viral
950 emission: Quanta emission rate of SARS-CoV-2 for infection risk as-
951 sessment, *Environment International* 141 (May) (2020) 105794. doi:
952 10.1016/j.envint.2020.105794.
- 953 [41] D. K. Milton, M. P. Fabian, B. J. Cowling, M. L. Grantham, J. J.
954 McDevitt, Influenza Virus Aerosols in Human Exhaled Breath: Particle

- 955 Size, Culturability, and Effect of Surgical Masks, *PLoS Pathogens* 9 (3)
956 (2013). doi:10.1371/journal.ppat.1003205.
- 957 [42] P. Fabian, J. J. McDevitt, W. H. DeHaan, R. O. Fung, B. J. Cowling,
958 K. H. Chan, G. M. Leung, D. K. Milton, Influenza virus in human
959 exhaled breath: An observational study, *PLoS ONE* 3 (7) (2008) 5–10.
960 doi:10.1371/journal.pone.0002691.
- 961 [43] K. K. Coleman, D. J. W. Tay, K. S. Tan, S. W. X. Ong, T. S. Than,
962 M. H. Koh, Y. Q. Chin, H. Nasir, T. M. Mak, J. J. H. Chu, D. K. Milton,
963 V. T. K. Chow, P. A. Tambyah, M. Chen, K. W. Tham, Viral Load of
964 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in
965 Respiratory Aerosols Emitted by Patients With Coronavirus Disease
966 2019 (COVID-19) While Breathing, Talking, and Singing, *Clinical*
967 *Infectious Diseases* 2 (Xx) (2021) 1–7. doi:10.1093/cid/ciab691.
968 URL [https://academic.oup.com/cid/advance-article/doi/10.](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab691/6343417)
969 1093/cid/ciab691/6343417
- 970 [44] F. K. Gregson, N. A. Watson, C. M. Orton, A. E. Haddrell, L. P. Mc-
971 Carthy, T. J. Finnie, N. Gent, G. C. Donaldson, P. L. Shah, J. D.
972 Calder, B. R. Bzdek, D. Costello, J. P. Reid, Comparing aerosol concen-
973 trations and particle size distributions generated by singing, speaking
974 and breathing, *Aerosol Science and Technology* 55 (6) (2021) 681–691.
975 doi:10.1080/02786826.2021.1883544.
976 URL <https://doi.org/10.1080/02786826.2021.1883544>
- 977 [45] G. R. Johnson, L. Morawska, The mechanism of breath aerosol forma-

- 978 tion, *Journal of Aerosol Medicine and Pulmonary Drug Delivery* 22 (3)
979 (2009) 229–237. doi:10.1089/jamp.2008.0720.
- 980 [46] G. R. Johnson, L. Morawska, Z. D. Ristovski, M. Hargreaves,
981 K. Mengersen, C. Y. Chao, M. P. Wan, Y. Li, X. Xie, D. Kato-
982 shevski, S. Corbett, Modality of human expired aerosol size distri-
983 butions, *Journal of Aerosol Science* 42 (12) (2011) 839–851. doi:
984 10.1016/j.jaerosci.2011.07.009.
- 985 [47] L. Morawska, G. R. Johnson, Z. D. Ristovski, M. Hargreaves,
986 K. Mengersen, S. Corbett, C. Y. Chao, Y. Li, D. Katoshevski, Size
987 distribution and sites of origin of droplets expelled from the human res-
988 piratory tract during expiratory activities, *Journal of Aerosol Science*
989 40 (3) (2009) 256–269. doi:10.1016/j.jaerosci.2008.11.002.
- 990 [48] O. O. Adenaiye, J. Lai, P. J. B. de Mesquita, F. Hong, S. Youssefi,
991 J. German, S.-H. S. Tai, B. Albert, M. Schanz, S. Weston, J. Hang,
992 C. Fung, H. K. Chung, K. K. Coleman, N. Sapoval, T. Treangen,
993 I. M. Berry, K. Mullins, M. Frieman, T. Ma, D. K. Milton, Infec-
994 tious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks Dur-
995 ing Early Mild Infection, *medRxiv* (2021) 1–19arXiv:2021.08.13.
996 21261989, doi:<https://doi.org/10.1101/2021.08.13.21261989>.
997 URL <https://doi.org/10.1101/2021.08.13.21261989>
- 998 [49] V. M. Corman, I. Eckerle, T. Bleicker, A. Zaki, O. Landt, M. Eschbach-
999 Bludau, S. van Boheemen, R. Gopal, M. Ballhause, T. M. Bestebroer,
1000 D. Muth, M. A. Müller, J. F. Drexler, M. Zambon, A. D. Osterhaus,
1001 R. M. Fouchier, C. Drosten, Detection of a novel human coronavirus by

1002 real-time reverse-transcription polymerase chain reaction, Eurosurveil-
1003 lance 17 (39) (2012) 1–6. doi:10.2807/ese.17.39.20285-en.
1004 URL <http://dx.doi.org/10.2807/ese.17.39.20285-en>